Human Interleukin-11 Recombinant

Catalog #
90176-A
$130 *
Size: 2 µg
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human interleukin-11 (IL-11), also known as oprelvekin, is a disulfide-linked monomeric protein consisting of 180 amino acids and migrates as an approximately 19 kDa protein under reducing and non-reducing conditions. Optimized DNA sequence encoding human IL-11 mature chain was expressed in E. coli.

Synonyms
IL-11, IL11, Oprelvekin, Interleukin-11
Product Info
Storage and Usage
Citations
Species
Human
Host Species/Expression System
E. coli
Purity
≥97% by SDS-PAGE and HPLC
Format
lyophilized protein
Formulation

Lyophilized from 0.2 µm filtered phosphate buffered solution in 2.5% glycine, pH 4.5.

MW
19 kDa
Endotoxin Level
Endotoxin level was found to be < 0.1 ng/μg (1EU/μg), using the LAL gel clot method.
Biological Activity
The ED50 was determined by the dose-dependent stimulation of the proliferation of murine T11 cells is ≤ 1.0 ng/ml, corresponding to a specific activity of > 1 x 106units/mg.
UniProt #
P20809
Background
IL-11 is secreted by bone marrow stromal cells (fibroblasts)and is produced also by a number of mesenchymal cells. The IL-11 receptor (alpha chain) utilizes gp130 as its signal transducer, which is also a component of other cytokine receptors. The alpha chain of the IL-11 receptor has been identified independently as Etl2. IL-11 promotes primary and secondary immune responses in vitro and in vivo and modulates antigen-specific antibody reactions. IL-11 promotes the proliferation of IL-6 dependent plasmacytoma cell lines in the presence of neutralizing IL-6 antibodies. IL-11 also stimulates the T-cell dependent development of IgG-secreting B-cells in spleen cell cultures. IL-11 inhibits the differentiation of pre- adipocytes. It induces the synthesis of some acute phase proteins by hepatocytes.
References
1. J. Immunol., Oct 2009, 183: 4229 - 4240.
2. Am. J. Respir. Cell Mol. Biol., Dec 2008, 39: 739 - 746.
3. Invest. Ophthalmol. Vis. Sci., May 2007, 48: 2524.